These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 24055694)

  • 61. Higher Serum Trough Levels of Tacrolimus Increase 5-Year Allograft Survival in Antibody Positive Renal Transplant Patients.
    Peng ZG; Tian J
    Clin Transpl; 2014; ():209-14. PubMed ID: 26281147
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Pretransplant soluble CD30 is a better predictor of posttransplant development of donor-specific antibodies and acute vascular rejection than panel reactive antibodies.
    Vaidya S; Partlow D; Barnes T; Gugliuzza K
    Transplantation; 2006 Dec; 82(12):1606-9. PubMed ID: 17198244
    [TBL] [Abstract][Full Text] [Related]  

  • 63. High soluble CD30 levels and associated anti-HLA antibodies in patients with failed renal allografts.
    Karahan GE; Caliskan Y; Ozdilli K; Kekik C; Bakkaloglu H; Caliskan B; Turkmen A; Sever MS; Oguz FS
    Int J Artif Organs; 2017 Jan; 39(11):547-552. PubMed ID: 28058698
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Pretransplant serum IgA concentration and IgA-anti-Fab autoantibody activity as prognostic indicators of kidney graft survival.
    Süsal C; Dörr C; Groth J; May G; Opelz G
    Transpl Int; 1994; 7 Suppl 1():S586-9. PubMed ID: 11271315
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Graft-protective role of high pretransplantation IgA-anti-Fab autoantibodies: confirmatory evidence obtained in more than 4000 kidney transplants. The Collaborative Transplant Study.
    Süsal C; Döhler B; Opelz G
    Transplantation; 2000 Apr; 69(7):1337-40. PubMed ID: 10798750
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Pre-transplant angiotensin II type 1 receptor antibodies: A risk factor for decreased kidney graft function in the early post-transplant period?
    Hernández-Méndez EA; Arreola-Guerra JM; Morales-Buenrostro LE; Ramírez JB; Calleja S; Castelán N; Salcedo I; Vilatobá M; Contreras AG; Gabilondo B; Granados J; Alberú J
    Clin Transpl; 2013; ():343-50. PubMed ID: 25095527
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Immunoglobulin M-to-immunoglobulin G anti-human leukocyte antigen class II antibody switching in cardiac transplant recipients is associated with an increased risk of cellular rejection and coronary artery disease.
    Lietz K; John R; Burke E; Schuster M; Rogers TB; Suciu-Foca N; Mancini D; Itescu S
    Circulation; 2005 Oct; 112(16):2468-76. PubMed ID: 16230499
    [TBL] [Abstract][Full Text] [Related]  

  • 68. The effect of anti-human leukocyte antigen, anti-major histocompatibility complex class 1 chain-related antigen a, and anti-glutathione transferase-T1 antibodies on the long-term survival of renal allograft.
    Akgul SU; Oğuz FS; Çalışkan Y; Kekik C; Çağatay P; Türkmen A; Nane I; Aydın F; Temurhan S
    Transplant Proc; 2013 Apr; 45(3):890-4. PubMed ID: 23622580
    [TBL] [Abstract][Full Text] [Related]  

  • 69. TH1/TH2 cytokines and soluble CD30 levels in kidney allograft patients with donor bone marrow cell infusion.
    Solgi G; Amirzagar AA; Pourmand G; Mehrsai AR; Taherimahmoudi M; Baradaran N; Nicknam MH; Ebrahimi Rad MR; Saraji A; Asadpoor AA; Moheiydin M; Nikbin B
    Transplant Proc; 2009 Sep; 41(7):2800-4. PubMed ID: 19765439
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Complement-fixing antibodies against denatured HLA and MICA antigens are associated with antibody mediated rejection.
    Cai J; Terasaki PI; Zhu D; Lachmann N; Schönemann C; Everly MJ; Qing X
    Exp Mol Pathol; 2016 Feb; 100(1):45-50. PubMed ID: 26615783
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Soluble CD30 concentrations in ESRD patients with and without panel reactive HLA antibodies.
    Vaidya S; Partlow D; Barnes T; Thomas P; Gugliuzza K
    Clin Transplant; 2006; 20(4):461-4. PubMed ID: 16842522
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Strong human leukocyte antigen matching effect in nonsensitized kidney recipients with high pretransplant soluble CD30.
    Süsal C; Pelzl S; Opelz G
    Transplantation; 2003 Oct; 76(8):1231-2. PubMed ID: 14578759
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Good kidney transplant outcome in recipients with presensitization against HLA class II but not HLA class I.
    Süsal C; Opelz G
    Hum Immunol; 2004 Aug; 65(8):810-6. PubMed ID: 15336782
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Soluble CD30 as a prognostic factor for outcome following renal transplantation.
    Platt RE; Wu KS; Poole K; Newstead CG; Clark B
    J Clin Pathol; 2009 Jul; 62(7):662-3. PubMed ID: 19561239
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients.
    Schaefer SM; Süsal C; Opelz G; Döhler B; Becker LE; Klein K; Sickmüller S; Waldherr R; Macher-Goeppinger S; Schemmer P; Beimler J; Zeier M; Morath C
    HLA; 2016 Feb; 87(2):89-99. PubMed ID: 26840927
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Posttransplant major histocompatibility complex class I chain-related gene A antibodies and long-term graft outcomes in a multicenter cohort of 779 kidney transplant recipients.
    Lemy A; Andrien M; Lionet A; Labalette M; Noel C; Hiesse C; Delahousse M; Suberbielle-Boissel C; De Meyer M; Latinne D; Mourad M; Delsaut S; Racapé J; Wissing KM; Toungouz M; Abramowicz D
    Transplantation; 2012 Jun; 93(12):1258-64. PubMed ID: 22466790
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Kidney graft failure and presensitization against HLA class I and class II antigens.
    Süsal C; Opelz G
    Transplantation; 2002 Apr; 73(8):1269-73. PubMed ID: 11981420
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Donor-specific antibodies require preactivated immune system to harm renal transplant.
    Süsal C; Döhler B; Ruhenstroth A; Morath C; Slavcev A; Fehr T; Wagner E; Krüger B; Rees M; Balen S; Živčić-Ćosić S; Norman DJ; Kuypers D; Emonds MP; Pisarski P; Bösmüller C; Weimer R; Mytilineos J; Scherer S; Tran TH; Gombos P; Schemmer P; Zeier M; Opelz G;
    EBioMedicine; 2016 Jul; 9():366-371. PubMed ID: 27333031
    [TBL] [Abstract][Full Text] [Related]  

  • 79. High variation of individual soluble serum CD30 levels of pre-transplantation patients: sCD30 a feasible marker for prediction of kidney allograft rejection?
    Altermann W; Schlaf G; Rothhoff A; Seliger B
    Nephrol Dial Transplant; 2007 Oct; 22(10):2795-9. PubMed ID: 17616534
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
    Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
    Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.